Iovance Biotherapeutics Q1 2024 Financial Results Call on May 9, 2024

SAN CARLOS, Calif., May 01, 2024 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company dedicated to the advancement of polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, is set to announce its financial results for the first quarter of 2024 on Thursday, May 9, 2024. The company's management will conduct a conference call and live audio webcast at 4:30 p.m. ET on the same day to discuss the financial outcomes and provide a corporate update.

Interested parties can register to listen to the live or archived webcast, which is accessible in the Investors section of the company's website, IR.Iovance.com. The archived webcast will be available for a year.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is devoted to becoming the leading global entity in the innovation, development, and delivery of TIL therapies for cancer patients. By leveraging the human immune system to detect and eradicate various cancer cells in each individual patient, the company is pioneering a groundbreaking approach to cancer treatment. The Iovance TIL platform has shown encouraging clinical data across a range of solid tumors.

One of Iovance's significant achievements is Amtagvi™, which stands as the first FDA-approved T cell therapy specifically for a solid tumor indication. The company is committed to ongoing innovation in the field of cell therapy, including gene-edited cell therapy, with the aim of improving and extending the lives of cancer patients.

Amtagvi™ and its associated design marks, as well as Proleukin®, Iovance®, and IovanceCares™, are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks mentioned in the context refer to their respective owners.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!